A Phase 1 Study in Patients With Metastatic Castration-Resistant Prostate Cancer
Public ClinicalTrials.gov record NCT07719361. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, First-in-Human, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of FX-111 in Patients With Metastatic Castration-Resistant Prostate Cancer
Study identification
- NCT ID
- NCT07719361
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Flare Therapeutics Inc.
- Industry
- Enrollment
- 60 participants
Conditions and interventions
Conditions
- Metastatic Castration Resistant Prostate Cancer
- mCRPC
- mCRPC (Metastatic Castration-resistant Prostate Cancer)
- Prostatic Neoplasms
- Prostatic Neoplasms, Castration-Resistant
- mCRPC or Advanced/Metastatic Solid Tumors
- mCRPC, Metastatic Castration Resistant Prostate Cancer
- Neoplasms Prostate
- Neoplasms of Prostate
Interventions
- FX-111 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2026
- Primary completion
- Feb 14, 2028
- Completion
- Feb 14, 2029
- Last update posted
- Jul 21, 2026
2026 – 2029
United States locations
- U.S. sites
- 10
- U.S. states
- 8
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| START Los Angeles | Los Angeles | California | 90025 | Recruiting |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | Not yet recruiting |
| START Midwest | Grand Rapids | Michigan | 49546 | Recruiting |
| START New Jersey | East Brunswick | New Jersey | 08816 | Recruiting |
| START Carolinas | Myrtle Beach | South Carolina | 29572 | Recruiting |
| Tennessee Oncology | Nashville | Tennessee | 37203 | Not yet recruiting |
| START Dallas-Fort Worth | Fort Worth | Texas | 76104 | Recruiting |
| NEXT Houston | Houston | Texas | 77054 | Not yet recruiting |
| NEXT Oncology | San Antonio | Texas | 78229 | Not yet recruiting |
| NEXT Virginia | Fairfax | Virginia | 22031 | Not yet recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07719361, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 21, 2026 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07719361 live on ClinicalTrials.gov.